Mani Foroohar
Stock Analyst at Leerink Partners
(1.61)
# 3,161
Out of 4,843 analysts
174
Total ratings
44.68%
Success rate
-11.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.51 | +218.73% | 11 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $2.72 | +561.76% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.18 | +43.54% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $3.62 | +645.86% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.01 | +323.28% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.97 | +765.14% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $44.42 | +10.31% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $34.25 | +34.31% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.01 | +266.06% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $33.51 | +85.02% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $15.26 | -14.81% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.62 | +34.14% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $37.60 | +511.70% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $4.47 | -10.51% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.84 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.84 | +707.29% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.46 | +1,421.74% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $16.07 | +148.91% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $26.56 | +250.15% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $6.87 | +1,122.71% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.72 | +306.98% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $4.97 | +3,119.32% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $15.83 | +386.42% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $304.56 | -53.05% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $6.24 | -3.77% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $36.29 | +109.42% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.06 | +3,107.55% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.22 | +802.93% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.51
Upside: +218.73%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $2.72
Upside: +561.76%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.18
Upside: +43.54%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $3.62
Upside: +645.86%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.01
Upside: +323.28%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.97
Upside: +765.14%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $44.42
Upside: +10.31%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $34.25
Upside: +34.31%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.01
Upside: +266.06%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $33.51
Upside: +85.02%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $15.26
Upside: -14.81%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.62
Upside: +34.14%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $37.60
Upside: +511.70%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $4.47
Upside: -10.51%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.84
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.84
Upside: +707.29%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.46
Upside: +1,421.74%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $16.07
Upside: +148.91%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $26.56
Upside: +250.15%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $6.87
Upside: +1,122.71%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.72
Upside: +306.98%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $4.97
Upside: +3,119.32%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $15.83
Upside: +386.42%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $304.56
Upside: -53.05%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $6.24
Upside: -3.77%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $36.29
Upside: +109.42%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.06
Upside: +3,107.55%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.22
Upside: +802.93%